BMS to Acquire MyoKardia for ~$13.1B

Shots: BMS to acquire all the outstanding shares of MyoKardia’s common stock for $225.00/ share in cash, making a total deal value of ~$13.1B. The transaction is expected to be close in Q4’20 The acquisition will foster BMS’ CV portfolio with the addition of MyoKardia’s mavacamten. BMS expects to explore mavacamten in additional indications, including …

BMS to Acquire MyoKardia for ~$13.1B Read More »